Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives

Table 1 Comparison of the percentage inhibition of renal glucose reabsorption of different SGLT-inhibitors

Drug dosage	Filtered glucose (g/24 h) (eGFRx mean glucose mg/mL)	UGE (g/24 h)	Absorbed glucose (g/24 h)	Inhibition of glucose reabsorption (%)	References
Sotagliflozin 150 mg	256	36	220	14.1	Zambrowicz et al. [15]
Sotagliflozin 300 mg	287.5	47	240	16.5	Zambrowicz et al. [15]
Sotagliflozin 200 mg, 200 mg bid, 400 mg	–	~60	–	–	Rosentock et al. [36]
Empagliflozin 2.5 mg	–	–	–	39	Heise et al. [37]
Empagliflozin 10 mg	–	–	–	46
Empagliflozin 25 mg	–	–	–	58
Empagliflozin 100 mg	–	–	–	64
Dapagliflozin 2.5 mg	191.16	52	139.16	27.2	List et al. [38]
Dapagliflozin 5 mg	207.6	64	143.6	55.7
Dapagliflozin 10 mg	206.1	68	138.1	54.5
Dapagliflozin 20 mg	196.9	85	111.9	51.7
Dapagliflozin 50 mg	191.3	82	109.3	53.1

Inhibition of glucose reabsorption values, when not available, were calculated from the difference between filtered glucose (calculated as the product of estimated GFR [39] and estimated average glucose [40], HbA1c derived) and excreted glucose (g/24 h UGE)

ISSN: 1475-2840